Although GLP1 has been shown to have effects on the immune system, such as in cardiomyocytes (Noyn-Ashraf et al, 2009) or endothelial cells (Shiraki , et al, 2012), many of these studies have shown little relevance to the organ of interest, namely the pancreas
Federal rules around compounding can change depending on drug availability, patient-specific medical need, pharmacy type, and FDA enforcement priorities
In line with this observation, the pre-administration of DSePA (2 mg/Kg bodyweight) for five consecutive days significantly improved the 30-day survival of mice against the lethal dose (-rays, 10 Gy) of WBI by preventing lipid peroxidation, DNA damage, and apoptosis in the radiosensitive organs like the spleen and small intestine [88, 89]
Notably, in various clinical studies, DPP1 inhibitor treatment groups did not show significant increases in serious infection risk compared to placebo groups
Equation 1: Calculating an acceptable sample size for establishing homogeneity criteria
People with disorders that affect nutrient absorption such as celiac disease, chronic gastritis, and Crohns disease are especially susceptible to deficiencies
